Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781333 | 0.82 | SLC6A3 (0.38) | SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL1779901 | 0.71 | MEN1 (0.37) | SLC6A3SLC6A4CCR2 | |
| SCHEMBL1778995 | 0.70 | CCR2 (0.44) | SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL10390402 | 0.69 | CYP1A2 (0.34) | — | |
| SCHEMBL3984092 | 0.69 | ADAM17 (0.53) | SLC6A3SLC6A4CCR2 | |
| SCHEMBL8218564 | 0.66 | SLC6A4 (0.46) | SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL4728513 | 0.66 | SLC6A4 (0.46) | SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL8215573 | 0.66 | SLC6A4 (0.46) | SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL1772607 | 0.65 | CYP3A4 (0.37) | SLC6A3SLC6A4CCR2 | |
| SCHEMBL728522 | 0.65 | SLC6A3 (0.48) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507559-B2 | Cyclohexenyl modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2318352-B1 | CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| EP-2318352-A2 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010009068-A2 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | SLC6A3 4370/4885SLC6A4 3664/4885SLC6A2 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.